Going with the flow, and beyond, in myeloma

被引：2

作者：

Barlogie, Bart ^{[1
]}

Epstein, Joshua ^{[1
]}

Shaughnessy, John D., Jr. ^{[1
]}

机构：

[1] Univ Arkansas Med Sci, Little Rock, AR 72205 USA

来源：

BLOOD | 2008年 / 112卷 / 10期

关键词：

D O I：

10.1182/blood-2008-08-175026

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In this issue of Blood, Paiva and colleagues report that MFC performed on bone marrow examinations on day 100 after autotransplantation and intended to provide a measure of MRD in multiple myeloma distinguished patients with strikingly different progression-free and overall survival, independent of standard baseline prognostic variables and IFx-defined CR.

引用

页码：3917 / 3918

页数：2

共 8 条

[1] Role of autologous stem-cell transplantation in multiple myeloma [J].

Attal, Michel ;

Harousseau, Jean-Luc .

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2007, 20 (04) :747-759

[2] Making progress in treating multiple myeloma with total therapies: issue of complete remission and more [J].

Barlogie, B. ;

van Rhee, F. ;

Shaughnessy, J. D., Jr. ;

Anaissie, E. ;

Crowley, J. .

LEUKEMIA, 2008, 22 (08) :1633-1636

[3] Thalidomide and hematopoietic-cell transplantation for multiple myeloma [J].

Barlogie, B ;

Tricot, G ;

Anaissie, E ;

Shaughnessy, J ;

Rasmussen, E ;

van Rhee, F ;

Fassas, A ;

Zangari, M ;

Hollmig, K ;

Pineda-Roman, M ;

Lee, C ;

Talamo, G ;

Thertulien, R ;

Kiwan, E ;

Krishna, S ;

Fox, M ;

Crowley, J .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (10) :1021-1030

[4] Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma [J].

Cavo, M ;

Terragna, C ;

Martinelli, G ;

Ronconi, S ;

Zamagni, E ;

Tosi, P ;

Lemoli, RM ;

Benni, M ;

Pagliani, G ;

Bandini, G ;

Tura, S .

BLOOD, 2000, 96 (01) :355-+

[5] New drugs for myeloma [J].

Richardson, Paul G. ;

Mitsiades, Constantine ;

Schlossman, Robert ;

Munshi, Nikhil ;

Anderson, Kenneth .

ONCOLOGIST, 2007, 12 (06) :664-689

[6] A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1 [J].

Shaughnessy, John D. ;

Zhan, Fenghuang ;

Burington, Bart E. ;

Huang, Yongsheng ;

Colla, Simona ;

Hanamura, Ichiro ;

Stewart, James P. ;

Kordsmeier, Bob ;

Randolph, Christopher ;

Williams, David R. ;

Xiao, Yan ;

Xu, Hongwei ;

Epstein, Joshua ;

Anaissie, Elias ;

Krishna, Somashekar G. ;

Cottler-Fox, Michele ;

Hollmig, Klaus ;

Mohiuddin, Abid ;

Pineda-Roman, Mauricio ;

Tricot, Guido ;

van Rhee, Frits ;

Sawyer, Jeffrey ;

Alsayed, Yazan ;

Walker, Ronald ;

Zangari, Maurizio ;

Crowley, John ;

Barlogie, Bart .

BLOOD, 2007, 109 (06) :2276-2284

[7] The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma [J].

Tian, E ;

Zhan, FH ;

Walker, R ;

Rasmussen, E ;

Ma, YP ;

Barlogie, B ;

Shaughnessy, JD .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (26) :2483-2494

[8] Magnetic resonance imaging in multiple myeloma: Diagnostic and clinical implications [J].

Walker, Ronald ;

Barlogie, Bart ;

Haessler, Jeffrey ;

Tricot, Guido ;

Anaissie, Elias ;

Shaughnessy, John D., Jr. ;

Epstein, Joshua ;

van Hemert, Rudy ;

Erdem, Eren ;

Hoering, Antje ;

Crowley, John ;

Ferris, Ernest ;

Hollmig, Klaus ;

van Rhee, Frits ;

Zangari, Maurizio ;

Pineda-Roman, Mauricio ;

Mohiuddin, Abid ;

Yaccoby, Shmuel ;

Sawyer, Jeffrey ;

Angtuaco, Edgardo J. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (09) :1121-1128

← 1 →